Skip to main content

Astrocytoma

7
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
375%
Vaccine
125%
+ 4 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
2 programs
1
1
TemozolomidePhase 2
VorasidenibPhase 1Small Molecule
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
TemozolomidePhase 21 trial
VorasidenibPhase 1Small Molecule1 trial
Active Trials
NCT05484622Active Not Recruiting60Est. Aug 2027
NCT00783393Completed32Est. Jun 2005
Oncovir
OncovirDC - Washington
1 program
1
GAA/TT-peptide vaccine and poly-ICLCPhase 1Vaccine1 trial
Active Trials
NCT00795457Completed13Est. Jul 2015
Quadriga BioSciences
Quadriga BioSciencesCA - Los Altos
1 program
1
QBS10072SPhase 11 trial
Active Trials
NCT04430842Completed15Est. Dec 2022
Servier
ServierFrance - Suresnes
1 program
1
VorasidenibPhase 1Small Molecule1 trial
Active Trials
NCT07629089Not Yet Recruiting24Est. Jun 2035
Bristol Myers Squibb
1 program
CC-90010PHASE_12 trials
Active Trials
NCT04324840Terminated184Est. Jul 2024
NCT04047303Terminated20Est. Jun 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Sharp TherapeuticsTemozolomide
ServierVorasidenib
Sharp TherapeuticsVorasidenib
Quadriga BioSciencesQBS10072S
Bristol Myers SquibbCC-90010
Bristol Myers SquibbCC-90010
OncovirGAA/TT-peptide vaccine and poly-ICLC

Clinical Trials (7)

Total enrollment: 348 patients across 7 trials

NCT00783393Sharp TherapeuticsTemozolomide

SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

Start: May 2003Est. completion: Jun 200532 patients
Phase 2Completed
NCT07629089ServierVorasidenib

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

Start: Jun 2026Est. completion: Jun 203524 patients
Phase 1Not Yet Recruiting
NCT05484622Sharp TherapeuticsVorasidenib

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Start: Jan 2023Est. completion: Aug 202760 patients
Phase 1Active Not Recruiting
NCT04430842Quadriga BioSciencesQBS10072S

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Start: Jul 2020Est. completion: Dec 202215 patients
Phase 1Completed
NCT04324840Bristol Myers SquibbCC-90010

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Start: Jul 2020Est. completion: Jul 2024184 patients
Phase 1Terminated
NCT04047303Bristol Myers SquibbCC-90010

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Start: Jan 2020Est. completion: Jun 202420 patients
Phase 1Terminated
NCT00795457OncovirGAA/TT-peptide vaccine and poly-ICLC

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

Start: Jan 2009Est. completion: Jul 201513 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.